Literature DB >> 20195567

[Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies].

D Roesch-Ely1, U Pfueller, C Mundt, U Müller, M Weisbrod.   

Abstract

Cognitive deficits in schizophrenia are a clinically relevant symptom dimension and one of the best predictors for functional outcome. Pharmacological treatment of cognitive deficits in schizophrenia is still a challenge. The objective of this article is to present a detailed review of the literature on strategies for the pharmacological treatment of cognitive deficits. It is not clear whether first-generation antipsychotics have a genuine positive influence on cognition. There is only sparse evidence for the positive effect of second-generation antipsychotics on cognitive processes. Furthermore it is not evident that second-generation antipsychotics are more beneficial than first-generation antipsychotics in the treatment of cognitive deficits. The add-on use of substances which directly influence cognitive processes, so-called cognition-enhancing drugs is more promising.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20195567     DOI: 10.1007/s00115-009-2919-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  103 in total

1.  Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment.

Authors:  T Sumiyoshi; M Matsui; S Nohara; I Yamashita; M Kurachi; C Sumiyoshi; K Jayathilake; H Y Meltzer
Journal:  Am J Psychiatry       Date:  2001-10       Impact factor: 18.112

2.  Another view of therapy for cognition in schizophrenia.

Authors:  William T Carpenter; James M Gold
Journal:  Biol Psychiatry       Date:  2002-06-15       Impact factor: 13.382

3.  Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain.

Authors:  H Hall; G Sedvall; O Magnusson; J Kopp; C Halldin; L Farde
Journal:  Neuropsychopharmacology       Date:  1994-12       Impact factor: 7.853

Review 4.  Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.

Authors:  T E Goldberg; D R Weinberger
Journal:  J Clin Psychiatry       Date:  1996       Impact factor: 4.384

5.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

6.  Impact of modafinil on prefrontal executive function in schizophrenia.

Authors:  Michael D Hunter; Venkatasubramanian Ganesan; Iain D Wilkinson; Sean A Spence
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

7.  The dose-dependent effect of methylphenidate on performance, cognition and psychophysiology.

Authors:  Nicholas J Cooper; Hannah Keage; Daniel Hermens; Leanne M Williams; David Debrota; C Richard Clark; Evian Gordon
Journal:  J Integr Neurosci       Date:  2005-03       Impact factor: 2.117

8.  Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia.

Authors:  David A Lewis; Raymond Y Cho; Cameron S Carter; Kevin Eklund; Sarah Forster; Mary Ann Kelly; Debra Montrose
Journal:  Am J Psychiatry       Date:  2008-10-15       Impact factor: 18.112

9.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

10.  Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.

Authors:  Andreas Wittorf; Stephanie Sickinger; Georg Wiedemann; Stefan Klingberg
Journal:  Arch Clin Neuropsychol       Date:  2008-02-12       Impact factor: 2.813

View more
  2 in total

1.  [Early dementia as primary syndrome of schizophrenia].

Authors:  F U Lang; R Klug; M Kunath; C Palm; I Uttner; M Jäger
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

2.  [Schizophrenia and bipolar disorder : Treatment of cognitive impairments].

Authors:  P Riedel; M N Smolka; M Bauer
Journal:  Nervenarzt       Date:  2018-07       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.